Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.05 (4.08%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.47m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Holding(s) in Company

23 Jul 2010 13:50

RNS Number : 8445P
Epistem Holdings plc
23 July 2010
Β 

Β 

Β 

Β 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

Β 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Epistem Holdings plc

Β 

2 Reason for the notification (please tick the appropriate box or boxes):

Β 

An acquisition or disposal of voting rights

x

Β 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

Β 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify):

Β 

3. Full name of person(s) subject to the notification obligation:

Β 

Β Helium Special Situations Fund

4. Full name of shareholder(s) (if different from 3.):

Β 

Β Euroclear Nominees Limited

5. Date of the transaction and date on which the threshold is crossed or reached:

Β 

Β 21st July 2010

6. Date on which issuer notified:

Β 

Β 22nd July 2010

7. Threshold(s) that is/are crossed or reached:

Β 

Β 10%

Β 

8. Notified details:

A: Voting rights attached to shares

Β 

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Β 600,000

600,000

807,500

807,500

10%

Β GB00B1VKB224

Β 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Β 

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

Β 

% of voting rights

Β 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Β 

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

Β 

Nominal

Delta

Β 

Β 

Total (A+B+C)

Β 

Number of voting rights

Percentage of voting rights

Β 807,500

10%

Β 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Β 

Proxy Voting:

Β 

10. Name of the proxy holder:

Β 

11. Number of voting rights proxy holder will cease to hold:

Β 

12. Date on which proxy holder will cease to hold voting rights:

Β 

Β 

13. Additional information:

Β 

14. Contact name:

Β 

Β John Rylands

15. Contact telephone number:

Β 

0161 606 7258

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLUOSURRBABUAR
Date   Source Headline
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn
25th Apr 20229:00 amRNSPrice Monitoring Extension
20th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:35 pmRNSPrice Monitoring Extension
4th Apr 20225:13 pmRNSDirector/PDMR Shareholding
4th Apr 202211:05 amRNSSecond Price Monitoring Extn
4th Apr 202211:00 amRNSPrice Monitoring Extension
4th Apr 20229:05 amRNSSecond Price Monitoring Extn
4th Apr 20229:00 amRNSPrice Monitoring Extension
31st Mar 20229:05 amRNSSecond Price Monitoring Extn
31st Mar 20229:00 amRNSPrice Monitoring Extension
29th Mar 202211:06 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
29th Mar 202210:00 amRNSNICE issues Medtech Innovation Briefing
29th Mar 20227:00 amRNSHalf-year Report
25th Mar 202211:05 amRNSSecond Price Monitoring Extn
25th Mar 202211:00 amRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
22nd Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20223:16 pmRNSPALOH study results published in JAMA Pediatrics
21st Mar 20229:05 amRNSSecond Price Monitoring Extn
21st Mar 20229:00 amRNSPrice Monitoring Extension
18th Mar 20224:41 pmRNSSecond Price Monitoring Extn
18th Mar 20224:36 pmRNSPrice Monitoring Extension
18th Mar 20222:05 pmRNSSecond Price Monitoring Extn
18th Mar 20222:00 pmRNSPrice Monitoring Extension
18th Mar 20222:00 pmRNSFirst NHS Deployments of Genedrive System for AIHL
17th Mar 20227:00 amRNSBoard appointment
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSFurther re Directorate Change
23rd Feb 20225:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20229:05 amRNSSecond Price Monitoring Extn
23rd Feb 20229:00 amRNSPrice Monitoring Extension
23rd Feb 20227:00 amRNSUpdate on Point of Care Covid Test
15th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSNotice of Results
21st Jan 202211:05 amRNSSecond Price Monitoring Extn
21st Jan 202211:00 amRNSPrice Monitoring Extension
20th Jan 20224:40 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
10th Jan 20229:06 amRNSSecond Price Monitoring Extn
10th Jan 20229:00 amRNSPrice Monitoring Extension
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.